semaglutide


( Last Updated : October 4, 2022)
Generic Name:
semaglutide
Project Status:
Active
Therapeutic Area:
Weight management
Manufacturer:
Novo Nordisk Canada Inc.
Call for patient/clinician input open:
Brand Name:
Wegovy
Project Line:
Reimbursement Review
Project Number:
SR0725-000
Call for patient/clinician input closed:
NOC Status at Filing:
Post NOC

Details


Manufacturer Requested Reimbursement Criteria1:
Novo Nordisk Canada Inc. requests that Wegovy™ (semaglutide injection) 2.4 mg is listed as an adjunct to a reduced calorie diet and increased physical activity for chronic weight management in adult patients with an initial body mass index (BMI) of • 35 kg/m2 or greater AND prediabetes.
Submission Type:
Initial
Fee Schedule:
Schedule A
Tumour Type:
N/A
Indications:
Wegovy (semaglutide injection) 2.4 mg is indicated as an adjunct to a reduced calorie diet and increased physical activity for chronic weight management in adult patients with an initial body mass index (BMI) of: • 30 kg/m2 or greater (obesity), or • 27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbidity such as hypertension, type 2 diabetes mellitus, dyslipidemia, or obstructive sleep apnea.
Recommendation Type:
Do not reimburse
Final Recommendation:
  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.

Key Milestones2

Call for patient/clinician input open09-Feb-22
Call for patient/clinician input closed01-Apr-22
Clarification:

- Patient input submission received from Obesity Canada and the Canadian Liver Foundation (joint), Gastrointestinal Society, Diabetes Canada, and Obesity Matters

Submission received10-Mar-22
Submission accepted24-Mar-22
Review initiated25-Mar-22
Draft CADTH review report(s) provided to sponsor for comment10-Jun-22
Deadline for sponsors comments21-Jun-22
CADTH review report(s) and responses to comments provided to sponsor15-Jul-22
Expert committee meeting (initial)27-Jul-22
Draft recommendation issued to sponsor10-Aug-22
Draft recommendation posted for stakeholder feedback18-Aug-22
End of feedback period02-Sep-22
Clarification:

- Deadline for patient groups and clinician groups to provide feedback on the draft recommendations is 06-Sep-2022

Final recommendation issued to sponsor and drug plans16-Sep-22
Final recommendation posted04-Oct-22
Deadline for sponsor to submit redaction requests on draft CADTH review report(s)30-Sep-22
CADTH review report(s) posted